A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas

Annals of Surgery

Volumn 256, Issue 6, 2012, Pages 946-954

  Rahbour, Goher ^a   Siddiqui, Muhammed R ^a   Ullah, Mohammad Rehan ^a   Gabe, Simon M ^a   Warusavitarne, Janindra ^a   Vaizey, Carolynne J ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

enterocutaneous; fistula; meta analysis; octreotide; somatostatin

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PLACEBO; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

CANCER MORTALITY; CINAHL; COCHRANE LIBRARY; CONTINUOUS INFUSION; DATA BASE; EMBASE; ENTEROCUTANEOUS FISTULA; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

HUMANS; INTESTINAL FISTULA; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84870063148     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318260aa26     Document Type: Review

References (33)

1. Raptis SS, Lehmann E, Dollinger HC, et al. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism. 1978;27:1321-1328.
2. Beglinger C, Drewe J. Somatostatin and octreotide: physiological background and pharmacological application. Digestion. 1999;60:2-8.
3. Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg. 2001;88:190-199.
4. Lloyd DA, Gabe SM, Windsor AC. Nutrition and management of enterocuta-neous fistula. Br J Surg. 2006;93:1045-1055.
5. Campos AC, Andrade DF, Campos GM, et al. A multivariate model to determine prognostic factors in gastrointestinal fistulas. J Am Coll Surg. 1999;188:483-490.
6. Haffejee AA. Surgical management of high output enterocutaneous fistu-lae: a 24-year experience. Curr Opin Clin Nutr Metabol Care. 2004;7:309-316.
7. Hollington P, Mawdsley J, Lim W, et al. An 11-year experience of enterocuta-neous fistula. Br J Surg. 2004;91:1646-1651.
8. Li J, Ren J, Zhu W, et al. Management of enterocutaneous fistulas:30-year clinical experience. Chin Med J (Engl). 2003;116:171-175.
9. Gayral F, Campion JP, Regimbeau JM, et al. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg. 2009;250:872-877.
10. Pérez GD, Acosta BM. Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201-995). G E N. 1994;48:209-218.
11. Hernandez-Aranda JC, Gallo-Chico B, Flores-Ramirez LA, et al. Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition. Nutr Hosp. 1996;11:226-229.
12. Isenmann RS, Schielke DJ, Möf-rl FK, et al. Adjuvant therapy with so-matostatin i.v. in postoperative fistulae of the pancreas, gall bladder and small intestine. A multicentre, randomised study. Akt Chi. 1994;29:96-99.
13. Jamil M, Ahmed U, Sobia H. Role of somatostatin analogues in the management of enterocutaneous fistulae. J Coll Physicians Surg Pak. 2004;14:237-240.
14. Leandros E, Antonakis PT, Albanopoulos K, et al. Somatostatin versus oc-treotide in the treatment of patients with gastrointestinal and pancreatic fistulas. Can J Gastroenterol. 2004;18:303-306.
15. Nubiola-Calonge P, Badia JM, Sancho J, et al. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet. 1987;2:672-674.
16. Sancho JJ, di Costanzo J, Nubiola P, et al. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocuta-neous fistula. Br J Surg. 1995;82:638-641.
17. Scott NA, Finnegan S, Irving MH. Octreotide and postoperative enterocu-taneous fistulae: a controlled prospective study. Acta Gastroenterol Belg. 1993;56:266-270.
18. Sitges-Serra A, Guirao X, Pereira JA, et al. Treatment of gastrointestinal fistulas with Sandostatin. Digestion. 1993;54:38-40.
19. Spiliotis J, Vagenas K, Panagopoulos K, et al. Treatment of enterocutaneous fistulas with TPN and somatostatin, compared with patients who received TPN only. Br J Clin Pract. 1990;44:616-618.
20. Torres AJ, Landa JI, Moreno-Azcoita M, et al. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial. Arch Surg. 1992;127:97-99; discussion 100.
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
22. Review Manager (RevMan) [computer program] v, Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration. 2011;5:1.
23. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta Analysis in Context. 2nd ed. London, UK: BMJ Publication Group; 2001:285-312.
24. Kusuhara K, Kusunoki M, Okamoto T, et al. Reduction of the effluent volume in high-output ileostomy patients by a somatostatin analogue, SMS 201-995. Int J Colorectal Dis. 1992;7:202-205.
25. Chalmers TC, Smith H, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2:31-49.
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
27. Rangel SJ, Kelsey J, Colby CE, et al. Development of a quality assessment scale for retrospective clinical studies in pediatric surgery. J Pediatr Surg. 2003;38:390-396; discussion 90-96.
28. Patel YC, Greenwood M, Panetta R, et al. Molecular biology of somatostatin receptor subtypes. Metabolism. 1996;45:31-38.
29. Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009;94:654-661.
30. BIAM. Lanreotide acetate. 2001 March. Available at: http://www.biam2.org/ www/Sub5041.html. Accessed September 30, 2011.
31. Deitel M. Elemental diet and enterocutaneous fistula. World J Surg. 1983;7:451-454.
32. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropan-creatic system. Ann Oncol. 2004;15:966-973.
33. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer. 1997;79:830-834.